Table 2:
Baseline characteristics of dialysis patients receiving eptifibatide versus abciximab before and after matching.
| Before matching | After matching | |||||||
|---|---|---|---|---|---|---|---|---|
| Eptifibatide (n=384) | Abciximab (n=100) | Standardized difference (%) | P value | Eptifibatide (n=384) | Abciximab (n=100) | Standardized difference (%) | P value | |
| Demographics | ||||||||
| Age (years) | 64.63 ± 11.73 | 64.18 ± 11.46 | −3.8% | 0.73 | 64.22 | 64.49 | 2.3% | 0.85 |
| Male | 55.5% | 53.0% | 5.0% | 0.66 | 49.0% | 53.0% | −8.0% | 0.57 |
| Body mass index (kg/m2) | 30.5 | 30.7 | 1.6% | 0.89 | 30.1 | 30.7 | 5.5% | 0.74 |
| White race | 66.7% | 45.0% | −45.3% | < 0.001 | 48.8% | 48.8% | 0.0% | >0.99 |
| Black or African American race | 30.5% | 48.0% | 37.3% | 0.001 | 47.8% | 45.6% | −4.6% | 0.44 |
| Comorbidities | ||||||||
| Current/recent smoker (within 1 year) | 20.3% | 18.0% | −5.8% | 0.61 | 19.2% | 21.5% | 5.7% | 0.67 |
| Hypertension | 95.1% | 97.0% | 9.3% | 0.41 | 97.9% | 96.1% | −8.6% | 0.42 |
| Dyslipidemia | 85.4% | 81.0% | −12.2% | 0.28 | 82.1% | 86.7% | 12.7% | 0.37 |
| Family history of premature CAD | 15.4% | 10.0% | −15.3% | 0.17 | 13.2% | 11.4% | −5.0% | 0.69 |
| Prior MI | 36.5% | 52.0% | 32.0% | 0.005 | 48.8% | 47.9% | −2.0% | 0.88 |
| Prior heart failure | 45.3% | 52.0% | 13.4% | 0.23 | 48.3% | 51.1% | 5.7% | 0.68 |
| Prior valve surgery/procedure | 1.6% | 4.0% | 17.1% | 0.13 | 2.2% | 4.2% | 14.2% | 0.39 |
| Prior PCI | 40.6% | 50.0% | 19.0% | 0.092 | 44.9% | 48.6% | 7.3% | 0.57 |
| Prior CABG | 16.1% | 25.0% | 23.1% | 0.040 | 22.0% | 22.0% | 0.0% | >0.99 |
| Cerebrovascular disease | 25.0% | 29.0% | 9.1% | 0.42 | 30.2% | 27.5% | −6.1% | 0.67 |
| Peripheral arterial disease | 28.1% | 35.0% | 15.1% | 0.18 | 32.5% | 30.7% | −4.1% | 0.76 |
| Chronic lung disease | 25.3% | 30.0% | 10.8% | 0.34 | 29.0% | 29.2% | 0.5% | 0.97 |
| Diabetes mellitus | 68.2% | 73.0% | 10.3% | 0.36 | 73.3% | 72.9% | −1.0% | 0.94 |
| Heart failure within 2 weeks | 26.0% | 35.0% | 20.0% | 0.076 | 27.5% | 31.0% | 7.8% | 0.56 |
| Cardiomyopathy or left ventricular systolic dysfunction | 17.4% | 23.0% | 14.3% | 0.20 | 18.3% | 22.1% | 9.8% | 0.45 |
| Cardiogenic shock within 24 hours | 3.9% | 7.0% | 14.8% | 0.19 | 1.5% | 0.9% | −2.9% | 0.48 |
| Cardiac arrest within 24 hours | 2.3% | 2.0% | −2.3% | 0.84 | 0.0% | 0.0% | 0.0% | >0.99 |
| Pre-PCI left ventricular ejection fraction (%) | 48.0 ± 12.9 | 46.4 ± 13.0 | −12.2% | 0.28 | 47.8 | 47.5 | −1.9% | 0.87 |
| Pre-procedure hemoglobin (g/dL) | 11.3 ± 2.1 | 10.7 ± 1.6 | −31.4% | < 0.001 | 11.0 | 10.8 | −8.1% | 0.47 |
| CAD Presentation | ||||||||
| No symptom, no angina | 7.3% | 4.0% | −13.2% | 0.24 | 4.5% | 4.5% | 0.0% | >0.99 |
| Symptom unlikely to be ischemic | 1.3% | 3.0% | 13.3% | 0.25 | 1.2% | 1.2% | 0.0% | >0.99 |
| Stable angina | 9.4% | 8.0% | −4.8% | 0.67 | 10.1% | 10.1% | 0.0% | >0.99 |
| Unstable angina | 31.0% | 28.0% | −6.5% | 0.56 | 30.5% | 30.5% | 0.0% | >0.99 |
| Non-STEMI | 32.0% | 42.0% | 21.1% | 0.061 | 40.6% | 40.6% | 0.0% | >0.99 |
| STEMI or equivalent | 19.0% | 15.0% | −10.4% | 0.36 | 13.1% | 13.1% | 0.0% | >0.99 |
| Pre- & Intra-procedural Antiplatelet therapy | ||||||||
| Clopidogrel | 75.8% | 71.0% | −10.8% | 0.33 | 79.2% | 74.5% | 11.1% | 0.42 |
| Prasugrel | 10.4% | 9.0% | −4.8% | 0.68 | 8.9% | 6.4% | 9.5% | 0.50 |
| Ticagrelor1 | 4.2% | 4.0% | −0.8% | 0.94 | 4.0% | 3.3% | 3.7% | 0.80 |
| Aspirin | 90.6% | 97.0% | 26.7% | 0.037 | 87.6% | 97.8% | −39.8% | 0.008 |
| Procedural Characteristics | ||||||||
| IABP | 4.2% | 6.0% | 8.8% | 0.43 | 1.8% | 1.8% | 0.0% | >0.99 |
| Other mechanical ventricular support | 1.8% | 4.0% | 14.6% | 0.19 | 1.2% | 1.2% | 0.0% | >0.99 |
| Femoral artery access site | 88.5% | 88.0% | −1.7% | 0.88 | 89.1% | 86.7% | −7.3% | 0.58 |
| Radial artery access site | 11.5% | 12.0% | 1.7% | 0.88 | 10.9% | 13.3% | 7.3% | 0.58 |
| Cardiogenic shock at start of PCI | 4.2% | 6.0% | 8.8% | 0.43 | 1.2% | 2.1% | 4.4% | 0.32 |
| PCI Indication | ||||||||
| Immediate PCI for STEMI | 17.4% | 12.0% | −14.7% | 0.19 | 12.7% | 12.1% | −1.4% | 0.67 |
| PCI for STEMI (Unstable, >12 hours from symptom onset) | 1.3% | 0.0% | −12.9% | 0.25 | 0.0% | 0.0% | 0.0% | >0.99 |
| PCI for STEMI (Stable, >12 hours from symptom onset) | 1.0% | 2.0% | 8.6% | 0.44 | 0.4% | 0.9% | 4.7% | 0.67 |
| PCI for STEMI (Stable after successful full-dose thrombolysis) | 0.0% | 0.0% | 0.0% | <0.001 | 0.0% | 0.0% | 0.0% | <0.001 |
| Rescue PCI for STEMI (after failed full-dose thrombolytic) | 0.0% | 1.0% | 22.1% | 0.050 | 0.0% | 0.0% | 0.0% | >0.99 |
| PCI for high risk Non-STEMI or unstable angina | 53.9% | 65.0% | 22.4% | 0.047 | 63.3% | 66.5% | 6.4% | 0.28 |
| Staged PCI | 0.8% | 0.0% | −9.9% | 0.38 | 0.0% | 0.0% | 0.0% | >0.99 |
| Other | 25.5% | 20.0% | −12.8% | 0.25 | 23.6% | 20.4% | −7.4% | 0.28 |
Data are presented as percentages (%) or means ± standard deviations where appropriate.
1
Data on ticagrelor administration was collected beginning on January 1, 2013.
Abbreviations: CAD=coronary artery disease; MI=myocardial infarction; PCI=percutaneous coronary intervention; CABG=coronary artery bypass grafting; STEMI=ST-segment elevation myocardial infarction; IABP=intra-aortic balloon pump.